Expression of p65 gene in experimental colon cancer under the influence of 5-fluorouracil given alone and in combination with hormonal modulation

Neoplasma

Volumn 51, Issue 4, 2004, Pages 319-324

  Melen Mucha, G ^a   Balcerczak, E ^a   Mucha, S ^a   Panczyk, M ^a   Lipa, S ^a   Mirowski, M ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

5 FU; Colon 38 cancer; Hormonal modulation; P65 gene

Indexed keywords

ANGIOPEPTIN; BROXURIDINE; FLUOROURACIL; SYNAPTOTAGMIN; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; GENE EXPRESSION; MOUSE; NICK END LABELING; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 3142689614     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. AGARWAL B, BHENDWAL S, HALMOS B, MOSS SF, RAMEY WG, HOLT PR. Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. Clin Cancer Res 1999; 5(8): 2223-2229.
2. BALCERCZAK E, BARTKOWIAK J, BLONSKI JZ, ROBAK T, MIROWSKI M. Expression of gene encoding P65 oncofetal protein in acute and chronic leukemias. Neoplasma 2002; 49:295-299.
3. BALCERCZAK E, MIROWSKI M, JESIONEK-KUPNICKA D, BARTKOWIAK J, KUBIAK R, WIERZBICKI R. p65 and c-erbB2 genes expression in breast tumors: comparison with some histological typing, grading and clinical staging. J Exp Clin Cancer Res 2003; 22(2): 247-53.
4. BALCERCZAK E, MIROWSKI M, SASOR A, WIERZBICKI R. Expression of p65, DD3 and c-erbB2 genes in prostate cancer. Neoplasma 2003; 50(2): 97-101.
5. BALCERCZAK M, BALCERCZAK E, PASZ-WALCZAK G, KORDEK R, MIROWSKI M. Expression of the p65 gene in patients with colorectal cancer: comparison with some histological typing, grading and clinical staging. EJSO 2004; 30: 266-270.
6. BORING CC, SQUIRES TS, TONG T. Cancer statistic. CA Cancer J Clin 1993; 43: 7-26.
7. CHOMCZYNSKI P, SACCHI N, Single-step method of RNA isolation by acid guanidinum thiocynate-phenol-chloroform extraction. Analytical Biochem 1987; 162: 156-159.
8. GAVRIELI Y, SHERMAN Y, BEN-SASSON SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992; 119(3): 439-501.
9. GRODSTEIN F, NEWCOMB PA, STAMPFER MJ. Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med 1999; 106: 574-582.
10. HANAUSEK M, WANG SC, BLONSKI JZ, KULESZA EP, WALASZEK Z, MIROWSKI M. Expression of an oncofetal 65-kDa phosphoprotein in lymphocytic and granulocytic leukemias. Int J Hematol 1996; 63(3): 193-203.
11. HANAUSEK M, SZEMRAJ J, ADAMS AK, WALASZEK Z. The oncofetal protein p65: a new member of the steroid/thyroid receptor superfamily. Cancer Detect Prev 1996; 20(2): 1-8.
12. KOSHIJI M, ADACHI Y, TAKETANI S, TAKEUCHI K, HIOKI K, IKEHARA S. Mechanisms underlying apoptosis induced by combination of 5-fluorouracil and interferon-gamma. Biochem Biophys Res Commun 1997; 240(2): 376-381.
13. LAMOTE J, WILLEMS G. Stimulating effect of pentagastrin on cancer cell proliferation kinetics in chemically induced colon cancer in rats. Reg Peptides 1988; 29: 1-9.
14. MELEN-MUCHA G, WINCZYK K, PAWLIKOWSKI M. Somatostatin analogue octreotide and melatonin inhibit bromodeoxyuridine incorporation into cell nuclei and enhance apoptosis in the transplantable murine Colon 38 cancer. Anticancer Res 1998; 18: 3615-3620.
15. MELEN-MUCHA G, WINCZYK K, PAWLIKOWSKI M. Effects of somatostatin analogs octreotide and lanreotide on the proliferation and apoptosis in Colon 38 tumors: interaction with 5-fluorouracil. Neuroendocrinol Lett 2000; 21: 137-142.
16. MELEN-MUCHA G. The combined effects of tamoxifen or proglumide with 5-fluorouracil on the growth of murine transplantable Colon 38 cancer. GI Cancer 2001; 3(5): 383-394.
17. MELEN-MUCHA G. Effects of short term treatment with pentagastrin, proglumide, tamoxifen given separately or together with 5-fluorouracil on the growth in the murine transplantable Colon 38 cancer. Neoplasma 2002: 48(2): 133-138.
18. MIROWSKI M, WALASZEK Z, SHERMAN U, HANAUSEK M. Comparative structural analysis of human and rat 65 kDa tumor associated phosphoproteins. Int J Biochem 1993; 25: 1865-1871.
19. MIROWSKI M, KLIJANIENKO J, WANG S, VIELH P, WALASZEK Z, HANAUSEK M. Serological and immunohistochemical detection of a 65-kDa oncofetal protein in breast cancer. Eur J Cancer 1994; 30A(8): 1108-1113.
20. MIROWSKI M, ROZALSKI M, KRAJEWSKA U, BALCERCZAK E, MLYNARSKI W, WIERZBICKI R. Induction of caspase 3 and modulation of some apoptotic genes in human acute promyelocytic leukemia HL-60 cells by carboplatin with amifostine. Polish J Pharmacol 2003; 55: 227-234.
21. NEWCOMB PA, SOLOMON C, WHITE E. Tamoxifen and risk of large bowel cancer in women with breast cancer. Breast Cancer Res Treat 1999; 53: 271-277.
22. NIEWIADOMSKA H, MIROWSKI M, STEMPIEN M, OLBORSKI B, BLONSKI JZ et al. A 65 kDa oncofetal protein (p65), proliferating cell nuclear antigen (PCNA) and Ki67 expression in breast cancer patients. Neoplasma 1998; 45(4): 216-222.
23. SALTZ L. Drug treatment of colorectal cancer. Drugs 1991; 42: 616-627.
24. TOKUNAGA K, TANIGUCHI H, YODA K, SHIMIZU M, SAKIYAMA S. Nucleotide sequence of a full-length cDNA for mouse cytoskeletal beta-actin mRNA. Nucleic Acids Res. 1986; 14(6): 2829-2836.
25. WANG S, MIROWSKI M, SHERMAN U, WALASZEK Z, HANAUSEK M. Monoclonal antibodies against a 65-kDa tumor-associated phosphoprotein: development and use in cancer detection. Hybridoma 1993; 12(2): 167-175.
26. WANG S, HANAUSEK M, WALASZEK Z, MIROWSKI M, KROKOS C, SORIANO TF. A new tumor marker (p65) facilitates the accurate detection of colorectal cancer. Proceedings of the American Association for Cancer Research 1994; 35: 231, no. 1381.